Literature DB >> 20006311

Mycobacterium tuberculosis ESX-1 system-secreted protein ESAT-6 but not CFP10 inhibits human T-cell immune responses.

Buka Samten1, Xisheng Wang, Peter F Barnes.   

Abstract

The secreted proteins of M. tuberculosis, early secreted antigenic target 6 kDa (ESAT-6) and culture filtrate protein 10 kDa (CFP10), have been identified as antigenic proteins with potent T-cell stimulatory effects, and therefore have been the focus of tuberculosis vaccine studies. However, recent work showed that secretion of these proteins by the specialized ESAT-6 secretion system (ESX)-1 of M. tuberculosis is associated with virulence and pathogenesis. The studies demonstrated that ESAT-6 inhibits antigen-presenting cell function by reducing IL-12 production by macrophages through interrupting TLR2 signaling pathways and inducing macrophage apoptosis. However, the effect of ESAT-6 on T cells remains unexplored. To address this question, we studied the effect of recombinant ESAT-6 and CFP10 on human primary T-cell IFN-gamma secretion and proliferation. ESAT-6, but not CFP10, inhibited IFN-gamma production by T cells stimulated with M. tuberculosis or with anti-CD3 plus anti-CD28, in a dose-dependent manner. ESAT-6 also inhibited T-cell production of IL-17 and TNF-a, but not IL-2. Presence of CFP10 as part of the ESAT-6/CFP10 heterodimer did not affect ESAT-6 inhibition of T-cell IFN-gamma production. ESAT-6 inhibited the proliferation of CD3+ cells in response to TCR stimulation. ESAT-6 decreased T-cell IFN-gamma secretion by mechanisms independent of cytotoxicity or apoptosis. ESAT-6 reduced IFN-gamma mRNA levels by inhibiting the expression of the transcription factors, ATF-2, c-Jun and CREB, which upregulate IFN-gamma gene expression in T cells through binding to the IFN-gamma proximal promoter. ESAT-6, but not CFP10, bound to T cells and inhibited expression of early activation markers without reducing phosphorylation of ZAP70, a proximal TCR signaling molecule. We conclude that ESAT-6 directly inhibits human T-cell responses by affecting TCR signaling pathways downstream of ZAP70.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20006311     DOI: 10.1016/S1472-9792(09)70017-4

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  19 in total

1.  MprAB regulates the espA operon in Mycobacterium tuberculosis and modulates ESX-1 function and host cytokine response.

Authors:  Xiuhua Pang; Buka Samten; Guangxiang Cao; Xisheng Wang; Amy R Tvinnereim; Xiu-Lan Chen; Susan T Howard
Journal:  J Bacteriol       Date:  2012-10-26       Impact factor: 3.490

2.  Deletion of the β-Propeller Protein Gene Rv1057 Reduces ESAT-6 Secretion and Intracellular Growth of Mycobacterium tuberculosis.

Authors:  Jiafang Fu; Gongli Zong; Peipei Zhang; Yuanxin Gu; Guangxiang Cao
Journal:  Curr Microbiol       Date:  2017-11-13       Impact factor: 2.188

3.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

Review 4.  Innate immunity in tuberculosis: host defense vs pathogen evasion.

Authors:  Cui Hua Liu; Haiying Liu; Baoxue Ge
Journal:  Cell Mol Immunol       Date:  2017-09-11       Impact factor: 11.530

5.  Modulation of cell death by M. tuberculosis as a strategy for pathogen survival.

Authors:  Markos Abebe; Louise Kim; Graham Rook; Abraham Aseffa; Liya Wassie; Martha Zewdie; Alimuddin Zumla; Howard Engers; Peter Andersen; T Mark Doherty
Journal:  Clin Dev Immunol       Date:  2011-01-04

6.  Networked T cell death following macrophage infection by Mycobacterium tuberculosis.

Authors:  Stephen H-F Macdonald; Elliott Woodward; Michelle M Coleman; Emma R Dorris; Parthiban Nadarajan; Wui-Mei Chew; Anne-Marie McLaughlin; Joseph Keane
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

7.  Identification of Novel Potential Vaccine Candidates against Tuberculosis Based on Reverse Vaccinology.

Authors:  Gloria P Monterrubio-López; Jorge A González-Y-Merchand; Rosa María Ribas-Aparicio
Journal:  Biomed Res Int       Date:  2015-04-15       Impact factor: 3.411

8.  A peptide fragment from the human COX3 protein disrupts association of Mycobacterium tuberculosis virulence proteins ESAT-6 and CFP10, inhibits mycobacterial growth and mounts protective immune response.

Authors:  Sachin Kumar Samuchiwal; Sultan Tousif; Dhiraj Kumar Singh; Arun Kumar; Anamika Ghosh; Kuhulika Bhalla; Prem Prakash; Sushil Kumar; Maitree Bhattacharyya; Prashini Moodley; Gobardhan Das; Anand Ranganathan
Journal:  BMC Infect Dis       Date:  2014-07-01       Impact factor: 3.090

9.  A novel peptide interferes with Mycobacterium tuberculosis virulence and survival.

Authors:  Sachin Kumar Samuchiwal; Sultan Tousif; Dhiraj Kumar Singh; Arun Kumar; Anamika Ghosh; Kuhulika Bhalla; Prem Prakash; Sushil Kumar; Ashish Chandra Trivedi; Maitree Bhattacharyya; Gobardhan Das; Anand Ranganathan
Journal:  FEBS Open Bio       Date:  2014-08-07       Impact factor: 2.693

10.  ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.

Authors:  Truc Hoang; Claus Aagaard; Jes Dietrich; Joseph P Cassidy; Gregory Dolganov; Gary K Schoolnik; Carina Vingsbo Lundberg; Else Marie Agger; Peter Andersen
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.